Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.

ctDNA was studied for clinical significance in high-risk early HER2-negative breast cancer treated with neoadjuvant chemotherapy. The abstract does not name a commercial assay.

Cancer CellPubMed 37146605DOI 10.1016/j.ccell.2023.04.008